{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:28:41Z","timestamp":1790227721071,"version":"4.1.0"},"reference-count":17,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.3201\/eid3011.231416","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T13:56:12Z","timestamp":1729691772000},"source":"Crossref","is-referenced-by-count":4,"title":["Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs"],"prefix":"10.3201","volume":"30","author":[{"given":"Mayurika","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Iarikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing (Karen)","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Shurland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakshina","family":"Chilukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"McMaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sherwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3011.231416-202410091900-R1","unstructured":"US Food and Drug Administration. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases\u2014questions and answers (revision 1) guidance for industry, May 2022 [cited 2023 Jul 10]. https:\/\/www.fda.gov\/media\/158589\/download"},{"key":"key-10.3201\/eid3011.231416-202410091900-R2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"key":"key-10.3201\/eid3011.231416-202410091900-R3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/1469-0691.12363","article-title":"Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.","volume":"20","author":"Lemos","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"key-10.3201\/eid3011.231416-202410091900-R4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3011.231416-202410091900-R5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017.","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key-10.3201\/eid3011.231416-202410091900-R6","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1093\/cid\/ciad109","article-title":"Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex.","volume":"76","author":"Castanheira","year":"2023","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3011.231416-202410091900-R7","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3011.231416-202410091900-R8","doi-asserted-by":"publisher","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infections.","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3011.231416-202410091900-R9","unstructured":"US Food and Drug Administration. XACDURO (sulbactam for injection; durlobactam for injection) prescribing information. May 2023 [cited 2023 Jul 10]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216974Orig1s000Correctedlbl.pdf"},{"key":"key-10.3201\/eid3011.231416-202410091900-R10","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.","volume":"59","author":"Penwell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3011.231416-202410091900-R11","doi-asserted-by":"publisher","first-page":"709974","DOI":"10.3389\/fmicb.2021.709974","article-title":"Durlobactam, a new diazabicyclooctane \u03b2-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam.","volume":"12","author":"Shapiro","year":"2021","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid3011.231416-202410091900-R12","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3011.231416-202410091900-R13","unstructured":"US Food and Drug Administration. Sulbactam-durlobactam new drug application. Integrated review, application number: 216974Orig1s000 [cited 2024 Apr 29]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216974Orig1s000IntegratedR.pdf"},{"key":"key-10.3201\/eid3011.231416-202410091900-R14","unstructured":"US Food and Drug Administration. Demonstrating substantial evidence of effectiveness for human drug and biological products. Draft guidance for industry, December 2019 [cited 2023 Jul 10]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products"},{"key":"key-10.3201\/eid3011.231416-202410091900-R15","unstructured":"US Food and Drug Administration. Demonstrating substantial evidence of effectiveness with one adequate and well-controlled clinical investigation and confirmatory evidence, September 2023 [cited 2024 Apr 29. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/demonstrating-substantial-evidence-effectiveness-one-adequate-and-well-controlled-clinical"},{"key":"key-10.3201\/eid3011.231416-202410091900-R16","unstructured":"US Food and Drug Administration. Codevelopment of two or more new investigational drugs for use in combination, June 2013 [2024 Apr 29]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/codevelopment-two-or-more-new-investigational-drugs-use-combination"},{"key":"key-10.3201\/eid3011.231416-202410091900-R17","unstructured":"Antimicrobial Drugs Advisory Committee. Updated information: April 17, 2023: meeting of the Antimicrobial Drugs Advisory Committee meeting announcement [cited 2024 Aug 30]. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/updated-information-april-17-2023-meeting-antimicrobial-drugs-advisory-committee-meeting#event-materials"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/11\/23-1416_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T18:36:42Z","timestamp":1732905402000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/11\/23-1416_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3011.231416","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}